Skin Permeation of Rosiglitazone from Transdermal Matrix Patches - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Skin Permeation of Rosiglitazone from Transdermal Matrix Patches
The authors demonstrate that sustained-release delivery can help avoid the risk of sudden higher-blood concentration of a drug to avoid toxicity.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 56-72

References

1. E. Bonora et al., Diabetes 47 (10), 1643–1649 (1998).

2. S.M. Haffner et al., Diabetes 46 (1) , 63–69 (1997).

3. L.A. Werner and T.M. Travaglini, Pharmacotherapy 21 (9) , 1082–1099 (2001).

4. S.E. Nissen and K. Wolski, N. Engl. J. Med. 356 (24), 2457–2471 (2007).

5. S. Singh, Y.K. Loke, and C.D. Furberg, JAMA 298 (10), 1189–1195 (2007).

6. M. Hanefeld, Nat. Clin. Pract. Cardiovasc. Med. 4 (12), 648–649 (2007).

7. S.J. Baldwin, S.E. Clarke, and R.J. Chenery, Brit. J. Clin. Pharmacol. 48 (3), 424–432, (1999).

8. P.J. Cox et al., Drug Metab. Dispos. 28 (7), 772–780 (2000).

9. M. Segal, FDA Consum. 25 (8), 15–17 (1991).

10. P.P. Sarpotdar, J.L. Gaskill, and R.P. Giannini, J. Pharm. Sci. 75 (1), 26–28 (1986).

11. S. Proniuk , S.E. Dixon, and J. Blanchard, Pharm. Dev. Technol. 6 (3), 469–476 (2001).

12. B. Mukherjee et al., Eur J. Pharm. Biopharm. 59 (3), 475–483 (2005).

13. J. Fang et al., Biol. Pharm. Bull. 23 (11), 1357–1362 (2000).

14. B. Mukherjee et al., Pharm. Technol. 30 (3) , 146–163 (2006).

15. B. Mukherjee et al., J. Appl. Res. 5 (1), 96–108 (2005).

16. Y.W. Chien and K.H. Valia, Drug Dev. Ind. Pharm. 10 (4), 575–599 (1984).

17. N.S. Thomas and R. Panchagnula, Eur. J. Pharm. Sci. 18 (1), 71–79 2003.

18. B.L. Kolte et al., J. Chromatogr. B. Analyt. Technol. Biomed Life Sci. 788 (1), 37–44 (2003).

19. Y.W Chien, "Transdermal Therapeutic Systems," in Controlled Drug Delivery: Fundmentals and Applications, J.R. Robinson and V.H.L. Lee, Eds. (Marcel Dekker, New York, 2nd ed., 1987), pp. 524–552.

20. A.V. Pocius, "Adhesives," in Kirk-Othmer Encyclopedia of Chemical Technology, M. Howe-Grants, Ed. (Wiley-Interscience, New York, 1991), pp. 445–466.

21. A. Marini et al., J. Therm. Anal. Calorim. 73 (2), 547–561 (2003).

22. P. Arora and B. Mukherjee, J. Pharm. Sci. 91 (9), 2076–2089 (2002).

23. P.M. Satturwar, S.V. Fulzele, and A.K. Dorle, AAPS PharmSciTech. 6 (4), 49-54 (2005).

24. N.M Price et al., Clin. Pharmacol. Ther. 29 (3) , 414–420 (1981).

25. R.A. Codario, "Oral Agents for Type 2 Diabetes," in Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome: The Primary Guide to Diagnosis and Management, R.A. Codario, Ed. (Humana Press, Totowa, NJ, 2005), pp. 75–92.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here